Physician profile
Natan Khishchenko
NPI 1821202441
$22,435.21
in general payments reported to CMS, 2019-2025
48 companies · $6,586 in 2025
The $6,586 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $14.55 · 2021: $358 · 2022: $544 · 2023: $4,514 · 2024: $10K · 2025: $6,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,998 · Consulting Fee: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,420.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,998.00 |
| Consulting Fee | $1,950.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $10,712.02 | 2021-2025 | |
| Emd Serono, INC. | $2,632.12 | 2023-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,709.26 | 2022-2025 | |
| Biogen, INC. | $736.73 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Genentech USA, INC. | $648.44 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $504.90 | 2023-2025 | |
| Lundbeck LLC | $432.25 | 2023-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $367.84 | 2023-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $342.49 | 2020-2025 | Reyvow, Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $322.62 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $282.97 | 2021-2025 | Lokelma, Wainua |
| Ucb, INC. | $281.81 | 2023-2025 | Rystiggo, Nayzilam |
| Sk Life Science, INC. | $273.45 | 2023-2025 | |
| Amgen INC. | $259.84 | 2023-2025 | Aimovig, Uplizna |
| Jazz Pharmaceuticals INC. | $226.63 | 2024-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $196.36 | 2023-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $194.22 | 2023-2025 | |
| Celgene Corporation | $187.56 | 2022-2023 | Zeposia |
| Argenx US, INC. | $183.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $171.17 | 2023-2025 | Gocovri, Apokyn |
| Merz Pharmaceuticals, LLC | $169.55 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $165.17 | 2024-2025 | Hyqvia |
| Grifols USA, LLC | $126.23 | 2024-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $123.34 | 2024-2025 | Radicava |
| Csl Behring | $109.86 | 2024-2025 | Hizentra |
| Axsome Therapeutics, INC. | $97.31 | 2023-2025 | Sunosi, Symbravo |
| Otsuka America Pharmaceutical, INC. | $94.02 | 2023-2024 | Rexulti |
| Octapharma USA, INC. | $91.14 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Amneal Pharmaceuticals LLC | $84.98 | 2024-2025 | Crexont, Rytary |
| Novartis Pharmaceuticals Corporation | $74.95 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $68.69 | 2023-2024 | Onpattro |
| Neurelis, INC. | $58.79 | 2023-2024 | Valtoco |
| Kyowa Kirin, INC. | $58.24 | 2023-2024 | Nourianz |
| Eisai INC. | $51.00 | 2024 | |
| Acorda Therapeutics, INC | $43.12 | 2023 | Ampyra, Inbrija |
| Impel Pharmaceuticals INC. | $39.78 | 2023 | Trudhesa |
| Tonix Medicines, INC. | $39.45 | 2024-2025 | Zembrace Symtouch |
| Cycle Pharmaceuticals INC | $35.88 | 2025 | Tascenso Odt, Bafiertam |
| Catalyst Pharmaceuticals, INC. | $30.94 | 2023 | Firdapse |
| Supernus Pharmaceuticals, INC. | $30.62 | 2025 | Qelbree |
| Janssen Biotech, INC. | $27.45 | 2025 | |
| Kedrion Biopharma, INC. | $23.86 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Vanda Pharmaceuticals INC. | $23.83 | 2025 | Ponvory |
| Idorsia Pharmaceuticals US INC | $22.15 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $21.24 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.18 | 2025 | Dysport |
| Life Molecular Imaging LTD | $19.41 | 2025 | Neuraceq |
| Harmony Biosciences LLC | $17.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natan Khishchenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.